Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110972 | 0.90 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL30058901 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL23705003 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL8241636 | 0.85 | LMNA (0.39) | ALDH1A1KDM4EMAPTLMNACYP2C9 | |
| SCHEMBL23704889 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL8950117 | 0.79 | RARG (0.49) | ALDH1A1KDM4ELMNATDP1POLB | |
| SCHEMBL8776476 | 0.79 | RARG (0.49) | ALDH1A1KDM4ELMNATDP1POLB | |
| SCHEMBL7815408 | 0.77 | CA12 (0.44) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL15486875 | 0.75 | CA1 (0.41) | ALDH1A1KDM4EKDM1AMEN1KMT2A | |
| SCHEMBL6737923 | 0.75 | NPC1 (0.49) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294790-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| CN-1726042-A | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | ALDH1A1 1586/4885KDM4E 1238/4885MAPT 2812/4885 |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | ALDH1A1 1603/4885KDM4E 829/4885MAPT 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.